[Nuclear medicine and radiopharmaceuticals]

Area of Science:

• Nuclear Medicine
• Radiopharmaceutical Science

Background:

• Nuclear Medicine employs radiopharmaceuticals, which are drugs linked to radioactive isotopes, for advanced diagnostics and therapeutics.
• Radiopharmaceuticals are regulated as a special drug class in Europe, with diagnostic doses generally lacking pharmacological action or significant side effects.

Purpose of the Study:

• To highlight the importance of understanding radiopharmaceutical biodistribution and potential diagnostic errors.
• To discuss the growth of Nuclear Medicine driven by new radiopharmaceuticals and multimodality imaging.
• To emphasize the necessity of knowing imaging technique limitations and potential interferences.

Main Methods:

• Review of radiopharmaceutical applications in diagnostics and therapeutics.
• Analysis of regulatory policies for radiopharmaceuticals in Europe.
• Examination of factors influencing Nuclear Medicine advancements, including new radiotracers and imaging technologies like SPECT-CT, PET-CT, and PET-MRI.

Main Results:

• Alterations in radiopharmaceutical biodistribution represent the primary challenge, potentially leading to diagnostic inaccuracies.
• The field is expanding due to novel radiopharmaceuticals and integrated imaging modalities.
• Knowledge of technique limitations, physiological alterations, contraindications, and interferences is essential.

Conclusions:

• Accurate Nuclear Medicine practice requires comprehensive understanding of radiopharmaceutical behavior and imaging technology constraints.
• Continuous learning regarding new developments in radiopharmaceuticals and imaging is vital for clinicians.
• Mitigating diagnostic errors necessitates careful consideration of biodistribution, technique limitations, and potential adverse effects.